Significant
reduction in mortality in Chile from the use of the Chinese vaccine CoronaVac.
The
CoronaVac vaccine, developed by a Chinese company, provides 67% protection
against symptomatic disease and up to 80% protection against code 19 deaths.
This
was revealed in a study of millions of people in the real world in Chile.
The
Chilean health ministry said more than 10 million people had been included in
the study. Of these, 2.5 million were given both doses of the vaccine, while
1.5 million were given one dose between February 2 and April 1.
Diagnosis
of the disease was counted in corona cases 14 days after the second dose of the
vaccine.
You may also interested in the following post as well.
COVID-19ILLNESS CONCERNING SLEEP AND POOR HEALTH
FACEMASKS AND VENTILATION ARE MORE EFFECTIVE IN PREVENTING THE SPREAD OF COVID
HERBSHAVE VARIOUS BENEFITS, ESPECIALLY IN THE SITUATION OF CORONAVIRUS
Chinese
Sinovac COVID-19
China’s
Sinovac COVID-19 vaccine 67% effective in preventing symptomatic infection, Chile
govt report.
CoronaVac
is being used in many countries and according to the Chilean Ministry of
Health, its use reduces the risk of hospitalization from Corona by 85%, the
risk of getting to the ICU by 89%, and the risk of death by 80%.
This
is the largest study of any vaccine to date, and the research reports that have
emerged so far are limited to a limited group of thousands of people who have
been tested to test the efficacy and safety of vaccines.
Chile
leads South America in cod vaccination, with 40 percent of the population
receiving a single dose of the vaccine and 27 percent receiving both doses.
Chile
has agreed with Synovik to buy 60 million doses of CoronaVac over the next
three years, while the Pfizer vaccine is also being used there, but 90% of the
people have used CoronaVac.
The
study found that the use of the vaccine significantly reduced hospital admissions
for people aged 70 and over.
The
results of the CoronaVac in Brazil came out earlier this month. It was reported
that it provides 50.7% protection against the symptoms of COVID-19 diseases.
Similarly,
it is 83.7% effective in preventing cases that require treatment and 100%
effective in preventing mild and severe cases.
The
vaccine has also been approved for emergency use in Indonesia, where interim
data show it is up to 65% effective.
In a
trial in Turkey, the vaccine was found to be 83.5% effective in preventing
symptomatic disease and 100% effective in preventing serious illness.
Research
in Chile also found that people who took one dose of the vaccine had a higher
risk of developing the disease than those who took two doses.
It
should be noted that this vaccine has also been approved for use in Pakistan,
but it is difficult to say at present when it will be available.
For more information click here.
Comments